| Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission M Bocchia, A Sicuranza, E Abruzzese, A Iurlo, S Sirianni, A Gozzini, ... Frontiers in Oncology 8, 194, 2018 | 100 | 2018 |
| Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients G Caocci, B Martino, M Greco, E Abruzzese, MM Trawinska, S Lai, ... Experimental hematology 43 (12), 1015-1018. e1, 2015 | 64 | 2015 |
| Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE … G Caocci, O Mulas, E Abruzzese, L Luciano, A Iurlo, I Attolico, ... Hematological oncology 37 (3), 296-302, 2019 | 61 | 2019 |
| Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia … G La Nasa, G Caocci, R Littera, S Atzeni, A Vacca, O Mulas, M Langiu, ... Experimental hematology 41 (5), 424-431, 2013 | 45 | 2013 |
| Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second‐generation tyrosine kinase inhibitors in the real‐life practice: identification of risk … G Caocci, O Mulas, M Annunziata, L Luciano, M Bonifacio, EM Orlandi, ... American journal of hematology 93 (7), E159-E161, 2018 | 29 | 2018 |
| Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second-and third-generation tyrosine kinase inhibitors and role of secondary prevention G Caocci, O Mulas, M Bonifacio, E Abruzzese, S Galimberti, EM Orlandi, ... International Journal of Cardiology 288, 124-127, 2019 | 23 | 2019 |
| Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis G Caocci, O Mulas, D Mantovani, A Costa, A Galizia, L Barabino, M Greco, ... Annals of Hematology 101 (4), 929-931, 2022 | 22 | 2022 |
| Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second-and third-generation tyrosine kinase inhibitors G Caocci, O Mulas, M Annunziata, L Luciano, E Abruzzese, M Bonifacio, ... International Journal of Cardiology 301, 163-166, 2020 | 22 | 2020 |
| Conditioning regimens in patients with β-thalassemia who underwent hematopoietic stem cell transplantation: a scoping review O Mulas, B Mola, G Caocci, G La Nasa Journal of Clinical Medicine 11 (4), 907, 2022 | 18 | 2022 |
| HLA-G molecules and clinical outcome in chronic myeloid leukemia G Caocci, M Greco, M Arras, R Cusano, S Orrù, B Martino, E Abruzzese, ... Leukemia Research 61, 1-5, 2017 | 17 | 2017 |
| Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib G Caocci, O Mulas, I Capodanno, M Bonifacio, M Annunziata, ... Annals of hematology 100, 2005-2014, 2021 | 16 | 2021 |
| Risk and response-adapted treatment in multiple myeloma T Cazaubiel, O Mulas, L Montes, A Schavgoulidze, H Avet-Loiseau, ... Cancers 12 (12), 3497, 2020 | 15 | 2020 |
| Principal component analysis of the well-being at work and respect for Human Rights Questionnaire (WWRRR) in the Mediterranean region M Husky, Y Zgueb, U Ouali, CIA Gonzalez, M Piras, G Testa, A Maleci, ... Clinical Practice and Epidemiology in Mental Health: CP & EMH 16 (Suppl-1), 115, 2020 | 14 | 2020 |
| Arterial hypertension and tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and meta-analysis O Mulas, G Caocci, B Mola, G La Nasa Frontiers in Pharmacology 12, 674748, 2021 | 12 | 2021 |
| Metabolomic analysis of patients with chronic myeloid leukemia and cardiovascular adverse events after treatment with tyrosine kinase inhibitors G Caocci, M Deidda, A Noto, M Greco, MP Simula, O Mulas, D Cocco, ... Journal of clinical medicine 9 (4), 1180, 2020 | 12 | 2020 |
| Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second-or third … O Mulas, G Caocci, F Stagno, M Bonifacio, M Annunziata, L Luciano, ... Annals of Hematology 99, 1525-1530, 2020 | 11 | 2020 |
| Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice G Caocci, O Mulas, E Abruzzese, A Iurlo, M Annunziata, EM Orlandi, ... Annals of hematology 98, 1885-1890, 2019 | 11 | 2019 |
| Patient-physician communication in acute myeloid leukemia and myelodysplastic syndrome E Morelli, O Mulas, G Caocci Clinical Practice and Epidemiology in Mental Health: CP & EMH 17 (Supp-1), 264, 2021 | 10 | 2021 |
| Prognostic factors for overall survival in chronic myeloid leukemia patients: a multicentric cohort study by the Italian CML GIMEMA network G Specchia, P Pregno, M Breccia, F Castagnetti, C Monagheddu, ... Frontiers in Oncology 11, 739171, 2021 | 9 | 2021 |
| Pro-inflammatory and pro-oxidative changes during nilotinib treatment in CML patients: Results of a prospective multicenter front-line TKIs study (KIARO study) A Sicuranza, I Ferrigno, E Abruzzese, A Iurlo, S Galimberti, A Gozzini, ... Frontiers in oncology 12, 835563, 2022 | 8 | 2022 |
